Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed or Refractory Solid Tumours and Leukemias

Summary
Trial Details
Eligibility
Centres / Contacts

Official Title

Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed or Refractory Solid Tumours and Leukemias

Summary:

The purpose of this study is to test the safety of carfilzomib in children and young adults given in different doses in combination with cyclophosphamide and etoposide.

Trial Description

Primary Outcome:

Dose Limiting Toxicity of study treatment following NCI CTCAE v4.03
Maximum Tolerated Dose of study treatment

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

Browse the Glossary

These resources are provided in partnership with the Canadian Cancer Society